Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q4 Revenues Rise 8.3 Percent, Net Loss Balloons 71 Percent

NEW YORK, Feb. 10 (GenomeWeb News) - Luminex yesterday reported that fourth-quarter revenue increased 8.3 percent to $9.1 million from $8.4 million in the year-ago quarter.

 

R&D spending for the three months ended Dec. 31, 2004, increased 13 percent to $908,000 from $807,000 for the same quarter in 2003.

 

Net loss in the current quarter surged 71 percent to $1.1 million from $643,000 in the year-ago quarter.

 

The company had $36 million in cash and cash equivalents on hand as of Dec. 31.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.